Defining Retinal Structures Using Hyperspectral Retinal Imaging for Retinal and Optic Nerve Disease

What this Trial Is About

Researchers are evaluating hyperspectral retinal imaging as a new, non-invasive method to capture detailed images of the retina and optic nerve in both healthy people and those with eye diseases. This study aims to compare hyperspectral imaging with standard eye imaging techniques to identify retinal biomarkers linked to diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration. Around 1000 participants will take part in this research at ophthalmology clinics in Melbourne, Australia. Participants will undergo hyperspectral retinal imaging using specialized devices, including the Optina Diagnostics Metabolic Hyperspectral Retinal Camera and a prototype camera developed by the Centre for Eye Research Australia. This imaging captures the retina across multiple wavelengths to provide detailed spectral information beyond conventional photography. Alongside hyperspectral imaging, standard eye imaging tests such as OCT, OCT angiography, fundus photography, and autofluorescence will be performed for comparison. The study is observational and focuses solely on imaging analysis. During the study visit, participants will receive a full ophthalmic assessment including hyperspectral imaging and other standard imaging tests after pupil dilation. The collected images will be processed and analyzed using statistical and machine learning methods to extract detailed spectral data for each retinal pixel. Researchers will evaluate how well hyperspectral imaging can detect retinal diseases by comparing its data with established imaging biomarkers. The study will monitor the diagnostic performance of hyperspectral imaging throughout the data collection and analysis phases, with no therapeutic treatment involved.

Defining Retinal Structures Using Hyperspectral Retinal Imaging